491 related articles for article (PubMed ID: 31424371)
1. Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication.
Maeda K; Das D; Kobayakawa T; Tamamura H; Takeuchi H
Curr Top Med Chem; 2019; 19(18):1621-1649. PubMed ID: 31424371
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?
Garbelli A; Riva V; Crespan E; Maga G
Biochem J; 2017 Apr; 474(10):1559-1577. PubMed ID: 28446620
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments.
Menéndez-Arias L
Antiviral Res; 2013 Apr; 98(1):93-120. PubMed ID: 23403210
[TBL] [Abstract][Full Text] [Related]
5. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors.
Imamichi T
Curr Pharm Des; 2004; 10(32):4039-53. PubMed ID: 15579086
[TBL] [Abstract][Full Text] [Related]
6. The development of anti-HIV-1 drugs.
Lu XF; Chen ZW
Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
[TBL] [Abstract][Full Text] [Related]
7. [GESIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2015)].
Panel de expertos de GeSIDA y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2015 Oct; 33(8):543.e1-43. PubMed ID: 25959461
[TBL] [Abstract][Full Text] [Related]
8. Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries.
Gibson RM; Nickel G; Crawford M; Kyeyune F; Venner C; Nankya I; Nabulime E; Ndashimye E; Poon AFY; Salata RA; Kityo C; Mugyenyi P; Quiñones-Mateu ME; Arts EJ
Infect Dis Poverty; 2017 Dec; 6(1):163. PubMed ID: 29202874
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of a mercaptobenzamide and its prodrug for NCp7-targeted inhibition of human immunodeficiency virus.
Hartman TL; Yang L; Helfrick AN; Hassink M; Shank NI; George Rosenker K; Scerba MT; Saha M; Hughes E; Wang AQ; Xu X; Gupta P; Buckheit RW; Appella DH
Antiviral Res; 2016 Oct; 134():216-225. PubMed ID: 27568924
[TBL] [Abstract][Full Text] [Related]
10. "Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets.
Kang D; Song Y; Chen W; Zhan P; Liu X
Mol Biosyst; 2014 Aug; 10(8):1998-2022. PubMed ID: 24841339
[TBL] [Abstract][Full Text] [Related]
11. HIV type 1 integrase inhibitors: from basic research to clinical implications.
Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection.
Menéndez-Arias L; Alvarez M
Antiviral Res; 2014 Feb; 102():70-86. PubMed ID: 24345729
[TBL] [Abstract][Full Text] [Related]
13. [Progress in antiretroviral drugs].
Sugiura W
Uirusu; 2005 Jun; 55(1):85-94. PubMed ID: 16308534
[TBL] [Abstract][Full Text] [Related]
14. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
[TBL] [Abstract][Full Text] [Related]
15. New drugs for old.
Winston A; Stebbing J
J HIV Ther; 2005 Mar; 10(1):11-6. PubMed ID: 15951729
[TBL] [Abstract][Full Text] [Related]
16. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
[TBL] [Abstract][Full Text] [Related]
17. The Discovery and Development of Oxalamide and Pyrrole Small Molecule Inhibitors of gp120 and HIV Entry - A Review.
Motati DR; Uredi D; Watkins EB
Curr Top Med Chem; 2019; 19(18):1650-1675. PubMed ID: 31424369
[TBL] [Abstract][Full Text] [Related]
18. [The newest developments in anti-HIV-1 drugs].
Zhang XQ
Yao Xue Xue Bao; 2010 Feb; 45(2):194-204. PubMed ID: 21351429
[TBL] [Abstract][Full Text] [Related]
19. Fragment Based Strategies for Discovery of Novel HIV-1 Reverse Transcriptase and Integrase Inhibitors.
Latham CF; La J; Tinetti RN; Chalmers DK; Tachedjian G
Curr Top Med Chem; 2016; 16(10):1135-53. PubMed ID: 26324045
[TBL] [Abstract][Full Text] [Related]
20. Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains.
Yu F; Li W; Wang L; Dai Y; Lu X; Wang Q; Xie L; Jiang S
Molecules; 2018 Jul; 23(7):. PubMed ID: 30004408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
